Clinical trials
Relapsed or Refractory Large B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,708 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT07686263RecruitingPhase 3
Testing a new drug to prevent schizophrenia relapse
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
Bentonville, ArkansasAges 18–65 - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT07664176RecruitingPhase 1
Focused ultrasound plus nivolumab for children with brain tumors
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
Washington D.C., District of ColumbiaAges 3–25 - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Basking Ridge, New JerseyAges 18 years+ - NCT07661550Recruiting
Preventing smoking relapse after pregnancy with breastfeeding help
This trial tests whether breastfeeding support can help you stay smoke-free after your baby is born. You may join if you quit smoking during this pregnancy and want to learn more about caring for your baby and breastfeeding.
Buffalo, New YorkAges 18 years+ - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT07638553RecruitingPhase 3
Psilocybin to prevent alcohol relapse with depression
This study tests whether psilocybin (a psychedelic compound) can help people with severe alcohol use disorder stay sober longer, especially if they also have depression. Participants receive guided psilocybin sessions alongside counseling to reduce the risk of returning to heavy drinking.
BayonneAges 18 years+ - NCT07634380RecruitingPhase 1
Sitagliptin Plus Pembrolizumab for Advanced Kidney or Skin Cancer
This study tests whether adding sitagliptin (a diabetes medication) to pembrolizumab (an immunotherapy) can help patients with advanced kidney cancer or melanoma whose cancer stopped responding to previous immunotherapy treatments. The goal is to see if this combination can shrink tumors and improve survival.
Iowa City, IowaAges 18–99 - NCT07622277Recruiting
Teeth Alignment Stability After Braces: A Retention Study
This study compares how different face types maintain their bite after orthodontic braces are removed. Researchers will use 3D imaging to track whether teeth stay in their corrected positions during the retention phase (when you wear retainers).
Rohtak, HaryanaAges 18–45 - NCT07627568Recruiting
Studying a New Drug for Leukemia After Stem Cell Transplant
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
Freiburg im BreisgauAges 18 years+ - NCT06389968Recruiting
Light therapy for vision after optic neuritis in MS
This study tests whether light stimulation can help improve vision after optic neuritis in people with multiple sclerosis. It may offer a way to support eye recovery without medication.
Munich, BavariaAges 18–60 - NCT07616999Recruiting
Long-term follow-up study of early psychosis treatment
This study follows people who were part of an earlier research trial about medication management during their first psychotic episode. Researchers want to understand how those early treatment choices affected their recovery over the past 20 years.
Hong KongAges 18–65 - NCT07611838Recruiting
Predicting ABPA Recurrence Using Blood and Immune Markers
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
Jinan, ShandongAges 18–80 - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+ - NCT07604311RecruitingPhase 4
Preventing IgA nephropathy flare-ups with Nefecon
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Guangzhou, GuangdongAges 18–75 - NCT02572778Recruiting
Study using patient tumor samples in head and neck cancer
This study uses tumor tissue taken from people with head and neck cancer, then grows it in a lab to better understand the cancer and predict responses. If you have a new or returning cancer and can share key medical details and follow-up information, you may be able to take part.
BrusselsAges 18 years+ - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07598955RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Relapsed Thymoma or Thymic Carcinoma
This trial tests a new type of immune cell therapy called CAR-NK cells, which are designed to fight thymoma or thymic carcinoma (cancers of the thymus gland) that has come back or stopped responding to prior treatments. The goal is to see if these engineered cells can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+ - NCT06456827Recruiting
Bite force and bone changes after braces in different face types
This trial compares how bite force and bone turnover markers change during the retention phase (after braces) in people with high-angle and low-angle face types. It may help understand why some people have more relapse after braces.
Rohtak, HaryanaAges 18–45 - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 1,708 recruiting relapsed or refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.